CABA | tickerfilter.com

Fundamental analysis

14%

Profitability 4%

Dept financing 11%

Liquidity 50%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

5.51%

1 Month

-17.28%

3 Months

-41.55%

6 Months

-66.08%

1 Year

-89.34%

2 Year

-67.37%

Key data

Stock price

$2.31

P/E Ratio

0.00

DAY RANGE

$2.28 - $2.46

EPS

$0.00

52 WEEK RANGE

$2.01 - $26.35

52 WEEK CHANGE

-$89.03

MARKET CAP

275.018 M

YIELD

N/A

SHARES OUTSTANDING

48.849 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/14/2024

BETA

1.52

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,626,598

AVERAGE 30 VOLUME

$4,188,049

Company detail

CEO: Steven Nichtberger
Region: US
Website: www.cabalettabio.com
Employees: 50
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies.

CABA - Cabaletta Bio, Inc.